Myovant Sciences Ltd. (MYOV) and Moleculin Biotech Inc. (NASDAQ:MBRX) Comparison side by side

As Biotechnology companies, Myovant Sciences Ltd. (NYSE:MYOV) and Moleculin Biotech Inc. (NASDAQ:MBRX) are our subject to compare. And more specifically their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myovant Sciences Ltd. 14 0.00 N/A -4.08 0.00
Moleculin Biotech Inc. 1 0.00 N/A -0.51 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Myovant Sciences Ltd. and Moleculin Biotech Inc.


Table 2 shows us Myovant Sciences Ltd. and Moleculin Biotech Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myovant Sciences Ltd. 0.00% -590.4% -157%
Moleculin Biotech Inc. 0.00% -92.2% -65.2%


The Current Ratio and a Quick Ratio of Myovant Sciences Ltd. are 2.3 and 2.3. Competitively, Moleculin Biotech Inc. has 1.5 and 1.5 for Current and Quick Ratio. Myovant Sciences Ltd.’s better ability to pay short and long-term obligations than Moleculin Biotech Inc.

Analyst Ratings

The Recommendations and Ratings for Myovant Sciences Ltd. and Moleculin Biotech Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Myovant Sciences Ltd. 0 0 3 3.00
Moleculin Biotech Inc. 0 0 0 0.00

The upside potential is 241.07% for Myovant Sciences Ltd. with consensus target price of $23.67.

Institutional and Insider Ownership

Myovant Sciences Ltd. and Moleculin Biotech Inc. has shares owned by institutional investors as follows: 33.4% and 17.9%. About 56.5% of Myovant Sciences Ltd.’s share are owned by insiders. Competitively, 23.73% are Moleculin Biotech Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Myovant Sciences Ltd. -9.21% -18.18% -59.09% -61.14% -63.47% -56.12%
Moleculin Biotech Inc. -5.22% -12.1% -18.05% -20.44% -35.72% 4.81%

For the past year Myovant Sciences Ltd. had bearish trend while Moleculin Biotech Inc. had bullish trend.


On 4 of the 7 factors Moleculin Biotech Inc. beats Myovant Sciences Ltd.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womenÂ’s health and endocrine diseases. The companyÂ’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The company has an agreement with Mayo Clinic to enable additional research on its WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. It also has a strategic collaboration with the University of Bergen to develop immune stimulation drug, as well as to expand research on inhibition of brain metastasis by MoleculinÂ’s pre-clinical drug WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.